The world’s first vaccine to treat deadly cancerous brain tumors can potentially give patients years of extra life, a global clinical trial has concluded. The Guardian reports: A senior NHS doctor who was one of the trial’s chief investigators said the evidence showed DCVax had resulted in “astonishing” enhanced survival for patients. One patient in the 331-person multicenter global study lived for more than eight years after receiving DCVax. In Britain, 53-year-old Nigel French is still alive seven years after having it. If approved by medical regulators, DCVax would be the first new treatment in 17 years for newly diagnosed glioblastoma patients and the first in 27 years for people in whom it had returned. “The total results are astonishing,” said Prof Keyoumars Ashkan, a neurosurgeon at King’s College hospital in London who was the European chief investigator of the trial. “The final results of this phase three trial… offer fresh hope to patients battling with glioblastoma.”

Trial researchers found that newly diagnosed patients who had the vaccine survived for 19.3 months on average, compared with 16.5 months for those who received a placebo. Participants with recurrent glioblastoma who had had DCVax lived on average for 13.2 months after receiving it, compared with just 7.8 months for those who did not. Overall 13% of people who received it lived for at least five years after diagnosis, while just 5.7% of those in the control group did so, according to the results of the trial, which were published on Thursday in the Journal of the American Medical Association Oncology.

The vaccine is a form of immunotherapy, in which the body’s immune system is programmed to track down and attack the tumor. It is the first developed to tackle brain tumors. “The vaccine works by stimulating the patient’s own immune system to fight against the patient’s tumor. It provides a personalized solution, working with a patient’s immune system, which is the most intelligent system known to man,” said Ashkan. “The vaccine is produced by combining proteins from a patient’s own tumor with their white blood cells. This educates the white cells to recognize the tumor. “When the vaccine is administered, these educated white blood cells then help the rest of the patient’s immune system recognize the tumor as something it needs to fight against and destroy. Almost like training a sniffer dog.”

Read more of this story at Slashdot.

Source: Slashdot – Vaccine Shown To Prolong Life of Patients With Aggressive Brain Cancer